Check out the latest EY Biotechnology Report 2024

UK Life Science Trend Analysis 2024 The UK government published the Science & Technology Framework in early 2023, signaling a robust strategy for the growth of the science and technology sector, with a focus on increasing private investment in R&D. Potentially a result of this strategic push, biotech private equity funding experienced a slight rise both in terms of the amount raised and the number of funding rounds completed. Biotechnology remains the primary focus within the UK life science industry, representing 36% of all companies. Notably, half of the biotech firms…

Press release Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development • Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems • The collaboration will combine advanced in vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology for precision oncology medicines Edinburgh and Cambridge,…

Sandwich, Kent, UK / 18th June 2024 / Discovery Park, Kent’s thriving life science and innovation community, is preparing to welcome 300 healthcare innovators to its campus on Thursday 20th June for its second annual Innovation Summit, with only final spots remaining. This year’s summit has a focus on innovation in healthcare, taking a close look at trends in healthy ageing, breakthroughs in medicine and life science, and the role of digital collaboration in future healthcare delivery. The one day event at Discovery Park’s campus in Sandwich includes morning  keynote speeches from…

On Wednesday 15th May, Pharmaron hosted the 3rd Chemistry for Life Science Symposium. Academic and industry experts presented on the leading edge of drug discovery and process chemistry with speakers Professor Robert Phipps (University of Cambridge), Professor Ross Denton (University of Nottingham), Dr Sarah Skerratt (CHARM Therapeutics), Dr David Wilson (AstraZeneca), Dr Jeremy Parker (AstraZeneca) along with Dr Sébastien Campos (Pharmaron) and Dr Aaron Dumas (Pharmaron). The industry topics varied from early-stage drug discovery and the impact of AI, together with synthetic…

Accelerating Drug Discovery with the CCDC, AWS, and Intel: Curated Data Set of Protein Structures from the Protein Data Bank with Predicted Hydrogen Positions Now Available Cambridge, UK – 18 June 2024 – Thanks to the combined computing power of Amazon Web Services (AWS) and Intel, the CCDC announces that a potentially significant advancement in drug discovery has been achieved. A curated data set of protein structures from the Protein Data Bank (PDB) with predicted hydrogen positions is now available for download. This project was supported by an Intel RISE Technology Initiative contribution…

 AMSBIO offers a range of kits, media and reagents enabling development of food in a way that is not wasteful of our natural resources and is not detrimental to the environment or consumer health. Recent advances in biotechnological methods have enabled the development of cultured meat - meat grown in a laboratory using stem cell technology that mimics the texture, flavor, and nutritional value of conventional meat. Cultured meat has the potential to be less resource intensive through the lessening of animal husbandry and slaughter leading to knock on…

Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. In this article, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, explores the potential of PDCs and their role in shaping the future of drug discovery. In the pharma industry, it is widely acknowledged that drug target validation needs to be carried out more effectively. Drug discovery is…

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients Cambridge, Cambridgeshire (UK) and Cambridge, Massachusetts (US) 13th June 2024: Mursla Bio, a biotech company that is pioneering the way we diagnose and treat cancer, today announces that it has taken a significant strategic step by entering the US market and opening a new office in Cambridge, Massachusetts. This move marks an important milestone in establishing the company’s commercial and regulatory presence in support of its global customers. Mursla…

Sign up to the Linkers System and receive email notifications Access to new sales channels where leading manufacturers can directly access the database and engage with prospective partner companies.   What is Linkers? Linkers is a system where SMEs, Startups and Academia can directly respond to the needs of major Japanese manufacturers.   Find out more via the hyperlink above!